ChromoCure, Inc. Makes Key Appointment to Medical Advisory Board and Business Development Team

RENO, NV--(Marketwire - July 13, 2009) -

ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it has appointed Dr. Jay Ellenby, MD to its Advisory Board and business development team. Dr. Ellenby will assist the company in forming strategic alliances as well as promote the company’s technology and service to pathology labs throughout the Southeast United States.

The company intends to execute and timely update investors on the following:

-- Elimination of prior corporate debt and addition of new technology assets. -- Activation of OTC Disclosure Service. This will also remove the unwanted “Caveat Emptor” flag associated with the company’s prior operations. -- Further appointments of MDs and other industry professionals to the Company’s Advisory and Business Development Boards. -- Guidance on 2009 revenues and sales projections. -- New additions to the Company’s pathology and cancer lab revenue partners -- New installations of the Company’s Chromosomal Scanner -- New technology and vendor agreements for national joint venture marketing and sales -- Full business plan information and regular technology briefings on the company’s cancer detection technologies 

About Us

ChromoCure develops and provides cancer detection systems to diagnostic labs. The systems are provided by the Company and installed on a revenue sharing basis. The Company’s systems measure the unique genomic characteristic common to all cancers. This characteristic is never found in normal cells. The Company believes its detection technology has an effective accuracy of 100% for all cancers at all stages. The Company also applies its science and technology to non-toxic and non-invasive approaches to cancer therapy and cure research. Web: http://www.chromocure.com

Safe-Harbor Statement

This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company’s website version of this press release contains various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.